Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi Downunder nice to say hello to you !......
Yes I still have near 2 Millions MSEP. I still have faith in the Co. Of course I am not infallible !!!!......
Have a very very nice time
janet
Fung Derf CMKX I have now 2,000,000 (2 Millions) plus dividends. Keeping 2Millions just in case ......
Initially I had 60 millions. I did sell 2millions last month and bought Tnog at 0,0032 only 100K. I did incresead TNOG later selling MSEP......
janet
Please send me your fax # and I will send you my statement
where I di sell 56 millions CMKX some at 0,0009 and some at 0,0008.
janet
Hi chwdrhed I am also sorry for not be able to esplain better. The stocks I keep I do not consider them " stinkers"
as I have good feeling about. ( sixt sense you might call )...... since my English understanding is not very good I rely on my feeling wich is quite good for me.....
Difficult to esplain but it is my way of trading so far so good........
Good luck to you
janet
Hi Fung Derf whenever possible more than double !.....And for each stock I do sell all or in part depends......
In each case I buy VOLUME !!!!
Take care
janet
Hi chwdrhed no no no way they did not go strait up.......
By the way it was more than double
Good day
janet
Hi Phil you made a mistake. I did made with CMKX a good $45,000 less commission. Big difference !!!!.....Remember I sold 56Millions shares between 0,0009 and 0,0008.......
In Sterling theorie I consider that volume is the key !!!!
It takes very little increase to make good money.........
I need now a good drink lol.....
Have fun
janet
Hi chwdrhed since I know now what you mean by "stinkers".....
I would like to say that I am quite lucky in my choice and
not get in often in "stinkers".......but when "seldom" I get in one I sell very very very fast and try as fast to recover with another one .......
I trade in a very flexible way !!!.....
Good luck
janet
Good morning Fung-Derf I am smiling because you no gave up !.......
I did made quite well in selling some MSEP to buy TNOG and CYOS.( more than double) .....
Is this answear your question ?????.......
Looking now for another good play to make more than double lol......
Take care and have a good day
janet
Hi Phil you are in title to your way of thinking and please let me have my way
than kyou
janet
Good morning Phil, lol.....you make me smile !.....
Sterling post I took it as a guidance and in my point of you
if you procede carefully there is something worth it to consider. You know my English it is not very good and I cannot esplain my toughts the way I think it should be interesting to go about. Like everything take some leave some..........
We had once " Bo " that did esplain is way to use Sterling method and I tought was quite interesting and clever to follow.
Have a good day
and thank you for thinking of me
janet
LRP News
Good morning mick to you and to all a very good lucky day
janet
Lorus successfully completes Phase II study of GTI-2040 combination therapy for treatment of kidney cancer
via COMTEX
April 12, 2005
Promising disease stabilizations, tumor reductions
and favorable safety profile
TSX: LOR
AMEX: LRP
TORONTO, Apr 12, 2005 (Canada NewsWire via COMTEX) --
Lorus Therapeutics Inc. ('Lorus'), a biopharmaceutical company specializing in the development and commercialization of pharmaceutical products and technologies for the management of cancer, today announced completion of its Phase II trial of GTI-2040 in combination with capecitabine in patients with advanced and metastatic renal cell carcinoma.
GTI-2040 is a highly specific inhibitor of R2, a component of ribonucleotide reductase, which can behave as a malignant determinant for cancer growth and metastasis, and is abnormally elevated in renal cell carcinoma and many other cancers.
"We are pleased that the final results for the Phase II clinical trial have now confirmed the promising interim findings presented at the ENA meeting in September 2004, a leading forum for presenting clinical oncology research, organized jointly by the European Organization for Research and Treatment of Cancer (EORTC), the United States National Cancer Institute (NCI), and the American Association for Cancer Research (AACR) and published in the Eur J Cancer Supplements, Vol 2 No 8, p.136," said Dr Jim Wright, the CEO of Lorus.
All 33 patients entering this study had advanced disease with multiple metastatic sites, with or without prior removal of the primary kidney tumor. However, more than half (52%) of the patients on the recommended dose exhibited disease stabilization or better, including one confirmed partial response.
Durable tumor reductions observed at the recommended dose included 23 per cent reduction of tumor burden in a patient with a disease stabilization of 10 months duration, and 39 per cent reduction of tumor burden in a patient with a partial response to treatment of eight months duration.
Other durable disease stabilizations of four to nine months duration were also observed. In keeping with the company's goal of developing anticancer drugs with high safety characteristics, GTI-2040 was well tolerated when combined with a cytotoxic agent with expected adverse events.
Patients with rapidly progressing renal cell carcinoma often require a succession of different therapies, each with a low frequency of response, so there is a recognized need for new combination therapies to provide a benefit for as long as possible for a larger patient population.
Dr. Wright noted that in addition to the strategy of combination with chemotherapeutic agents to treat resistant kidney cancer patients with advanced metastases and rapidly progressing disease, Lorus plans to pursue a GTI-2040 clinical development program to evaluate GTI-2040 in combination with interferon immunotherapy for treatment of early diagnosed kidney cancer requiring systemic therapy.
About Lorus
Lorus is a biopharmaceutical company focused on the development and commercialization of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of eight clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin(R) is a registered trademark of Lorus Therapeutics Inc.
About GTI-2040
GTI-2040 is an antisense drug that specifically targets the R2 component of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. It has also been described as a malignant determinant that is elevated in a wide range of tumors, and through deregulation can cooperate with a variety of cellular cancer causing genes known as oncogenes to enhance tumor growth and metastatic potential. GTI-2040 showed significant antitumor activity against many different human tumors in preclinical studies. In addition to the clinical trial in renal cell cancer described above, GTI-2040 is currently the subject of a Clinical Trials Agreement with the United States National Cancer Institute (NCI) under which GTI-2040 will be tested in combination chemotherapy in six different clinical trials. All six of these trials have been initiated.
Forward Looking Statements
Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.
%SEDAR: 00002368EF
VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: http://www.newswire.ca/en/releases/orgDisplay.cgi?okey=92631
For further information: Contacts: Lorus Therapeutics Inc.:Bruce Rowlands, Senior Vice President, (416) 798-1200 ext. 338,browlands(at)lorusthera.com; Media Contacts: Eliza Walsh, Amy Banek, MansfieldCommunications, (416) 599-0024, (212) 370-5045, eliza(at)mcipr.com,
Hi mick can you please tell me if when your right you are still dreaming ?????? lololol !!!!......
Take care
janet
AWBI looks like there is no trading going on. What is happening ?????......
TIA
janet
Thank you mick. Did change my price to 0,0002 and got filled immediately !......
Good luck for a nice double
janet
HI I did put an order in to buy 2M AWBI at 0,0001 see what happen.......Hopefully easy double ?????.....
Thank you
janet
O.K. mick just find out at last !!!!.....lolol.....was quite easy actually. Thanks so very much
janet
Good morning mick. I am tempted to buy AWBI. Any news please if I should do it ?????.........
To you and to all a very very good luck in your trading
janet
thank you mick I appreciate
janet
Good afternoon VIKING163 I share this with you.
I did not made good money several times because I did sell too fast! I did not made good money several times because I did not sell fast enough!......
But when we have a good stock it is worth to keep it. Eventually it will be good and we will be happy to have hold.
Several stock I still regret that I become discourage after few month of doing nothing and sold for little profits when I could have made a little fortune!........
MBAH, OMOG,ADZR,USGA, MOBL among others.
This a good example for me.
I keep MSEP and give time.........
Keep faith and wishing good luck to you and to all
janet
LRP interesting news........still very very cheap.....
Lorus signs agreement with Japan's Sumitomo Pharmaceuticals and Koken Co. Ltd.
via COMTEX
April 5, 2005
- Lorus and a leading Japanese pharmaceutical company agree to
develop anticancer drug -
TSX: LOR
AMEX: LRP
TORONTO, Apr 05, 2005 (Canada NewsWire via COMTEX) --
Lorus Therapeutics Inc. ('Lorus'), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, announced that it has signed a collaboration agreement with Japan's leading pharmaceutical company, Sumitomo Pharmaceuticals Co. Ltd. and Koken Co. Ltd.
According to terms of the agreement, Lorus will provide Sumitomo proprietary antisense oligonucleotides complementary to Thioredoxin mRNA, specifically the lead drug candidate, GTI-2601. The collaboration agreement provides for Lorus, Sumitomo and Koken to jointly own the compounds that result from this collaboration (Lorus: Sumitomo and Koken, 1:1). Financial terms of this agreement were not disclosed.
Thioredoxin is involved in tumor formation, progression and metastasis (spread of tumor cells) by a variety of mechanisms. Tumor samples from patients with lung, colon, cervical, gastric and hepatocellular carcinoma, squamous cell carcinoma, myeloma, non-Hodgkins lymphoma, mesothelioma, and acute lymphocytic leukemia, show elevated levels of Thioredoxin. Furthermore, expression levels of Thioredoxin correlate with disease prognosis.
Over-expression of Thioredoxin has been linked with resistance to chemotherapeutic agents. Given these observations, reducing the level of Thioredoxin with antisense drug should interfere with multiple pathways that lead to cancer progression. Through an in vitro and in vivo screening process, Lorus has demonstrated that GTI-2601 has target and sequence specific anti-cancer activity in vitro, using cultured human cancer cells, and potent anti-tumor and anti-metastatic activity in vivo in animal models of human cancers.
Sumitomo and Koken have developed an advanced delivery system based on collagen complexed with macromolecules. Published data, from a study using a pre-clinical animal disease model, demonstrate that injection of the delivery technology complexed to antisense oligonucleotides is more effective than uncomplexed oligonucleotides.
Furthermore, improved efficacy was demonstrated at decreased doses. Coupled with an effective antisense drug like GTI-2601, against a proven cancer target, this technology holds much promise from efficacy, safety, manufacturing and commercial perspectives.
"We are pleased to collaborate with one of Japan's leading pharmaceutical companies and with a leading collagen company. We believe that this important value added delivery technology will provide a significant advantage from a scientific and commercial point of view to Lorus' portfolio of antisense drugs," said Lorus CEO Dr. Jim Wright.
About Lorus
Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of eight clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin(R) is a registered trademark of Lorus Therapeutics Inc.
Forward Looking Statements
Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.
%SEDAR: 00002368EF
VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: http://www.newswire.ca/en/releases/orgDisplay.cgi?okey=92631
For further information: Contacts: Lorus Therapeutics Inc.: BruceRowlands, Senior Vice President, (416) 798-1200 ext. 338,
Hi Deann looks like TNOG coming up nicely.........I have only
some not much......
Think about
janet
=========================================================
BB's Penny Haven TNOG ready to break .01 soon with charting ozone_park 4/4/2005 7:18:54 PM
BB's Penny Haven TNOG, imagine if it breaks through that channel... bottom_player55 4/4/2005 6:27:14 PM
BB's Penny Haven TNOG updated annotated chart: i_like_bb_stock 4/4/2005 6:08:02 PM
In reply to: Han2004fl who wrote msg# 52 Date:4/4/2005 5:15:06 PM
Post #of 55
OT: look at GLKCE throughout this week guys.
1) GLKCE got on SHO LIST after the Grandfather cause
2) It is the smoking gun of naked short blow up
3) Many broker firms do not allow you to buy but sell only
4) HOY: $4165 of course tons of shares flooded into the market after that but i believe it's the result from naked shorting which make it difficult to raise capital needed.
5) If naked shorts much covered, this is going to be good. The person who owns 100% of the company stock bought more.. then we have 15% guy .. eventhough more shares got issued but we don't know if they were restricted or not. It got increased from 1.2 area to 5 million shares.
6) After the R/S in early FEB to have 1.2 million shars through out FEB, over 140 million shares traded in 4 session after... Folk, that is over 100X of O/S. Possible? Only in America.
I hope management are smart to not settle for few $$$ out of it.. but HUGE ones.
Those who filed 100% and 15% ownership, i believe they can't sell their stock for one year. This is the key to prosperity to sharesholders.
I encourage anyone who like to see the naked shorts pay, to put in $100 or $200 in this stock. You could lose it or you could gain HUGE. Just a gamble portion of your money.
I have been telling friends to buy 5000 shares and let it sit there till all come out in the open. I think it's a good gamble money. 5,000 shares at $10 = $50,000; @$100 = $500,000
IMHO
Thank you Deann I will !!!
Imagine that today I was reading CYOS Board and a post caught my attention. It was about GLKCE. The poster said that we should all buy some 5000 shares......could be only gumble....
I was thinking about when a sudden inside feeling made me buy .........
So I did for fun .......Bought at 0,07 Sourprise sourprise it double !!!!.......
Take care
janet
Good evening mick, thank you for thinking about me.You are a real darling !!!!......
Hi Phil lol....I do not post on Sterling Board, only reading his board. Do not drink kool-aid.....I prefere guayava jus!
By the way I see many time this espression do not know what it means......maybe kindly you can please esplain to me.....
To you Fung Derf I have to say that I had many many "strange"
happening in my life .......today I am not affected no more.......
what bother me is my poor English way of writing!
Wishing all a beautiful time
janet
Good morning Kimberlite. You said it right! To each is own illusion !!!!.....
If Casavant is as good to us shareholders as Castro has been to his own peoples.....Well well....I wonder who is ending up with the money ?????.... To remember that the sad part with Cuban Revolution is that Cubans endanger their own life to flee the Country !!!! That is reality !!!!.....
Have a good week-end,
ans let keep Casavant dream as long as it last........
janet
Hi TFN lets hope lolol......The sooner the better !!!
Have a good time and the best as always
janet
Would like to see SPRL in this list.....
http://biz.yahoo.com/prnews/050317/nyth081_2.html
janet
Strat Petroleum Announces Agreement for Financing to Drill First Well at Ementajevskoje Oil Site
via COMTEX
March 15, 2005
TORONTO, Mar 15, 2005 (BUSINESS WIRE) --
Strat Petroleum, Ltd. (National Quotation Bureau: SPRL)
Strat Petroleum, Ltd. today announced the finalization of an agreement to receive funding to develop the first well at the Ementajevskoje field and complete a feasibility study of the site. The agreement finalized with the Aurora Capital Shefa Fund LP, allows the Company to immediately draw up to $1.5 million for the completion of drilling of the first well and provide working capital. The agreement allows Aurora Capital to participate in the project under one of two alternatives to be finalized at the completion of the feasibility study.
Under alternative one, Aurora would earn a 33% interest in the first well and upon 100% return of capital, its interest would be reduced to 25% for the life of the well; Alternative two would allow Aurora the right to a 5% royalty on gross revenues from well production for the life of the well and 10% in warrants of the invested amount to be exercised 12 months after investment at a 50% discount to market.
Strat Petroleum, Ltd.'s strategy is to enhance shareholder value through the acquisition of oil & gas properties with proven reserves or producing/capped wells. Should you wish any additional information on our projects or management team, please visit our website at www.stratpetroleum.com or contact our Investor Relations office. Due to the volume of interest we will make every effort to respond as promptly as possible.
Statements made in this press release regarding the Company's or management's intention, beliefs, expectations, or predictions for the future are forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. These risks, assumptions and uncertainties include: the ability to compete effectively in a rapidly evolving and price competitive marketplace; uncertainties of completing business transactions; uncertainties of raising necessary capital; no control over long term pricing; possible reductions in demand for our products and services due to competition or changes in industry conditions or political environment; changes in the nature of energy regulation in the Russian Federation, the United States and other countries; political risk; currency exchange risk; changes in business strategy; the successful integration of newly-acquired businesses; the impact of technological change; reliance on management and management contacts; and other risks that may be referenced from time to time in the Company's filings with the Securities and Exchange Commission.
SOURCE: Strat Petroleum, Ltd.
Strat Petroleum, Ltd. Kathy Bassi, 1-905-714-0058 www.stratpetroleum.com
Copyright Business Wire 2005
Wishing the very best to all. This board will be great!
janet
MSEP well done dsertrat !....
All the best
good night
janet
Hi TFN, what sourprise me is that so many peoples that say they strongly beleave in the MSEP Co...... but as soon as there is a "drop" they panic.......Either one beleave or do not!!! Every stock do retrace, so....
What's the problem ?????....... We will go up and stronger after each drop that might occur!!!!.......
Take care,
janet
Good evening TFN, I think like you. I also beleave that tomorrow MSEP will recover pretty fast. A friend of mine
ask me to buy for her and I have an order in at 0,065.Not sure it will fill at this price but we shall see.......
Good luck and the best for tomorrow !!!
janet
TFN I am only trying to get back what I have lost........
Cheers
janet
MSEP TFN I am really glad to see your post on R.B.
Hopefully we will make it and good !!!!!
I am holding as far as I can go !!!!......
Enjoy your trading
janet
Good morning TFN, one thing for sure we all will know in one way or the other !!!!......And this it is about time and it is good for all of us !!!......
As many did, I too moved on and what will be will be !!!!......
Have a great day,
Good luck to you and to all,
janet
CMKX from abother board,
Good day to all,
janet
===============================================================
« CLB00206 Message list / Reply to msg. / Post new msg. « Older / Newer »
By: jwravin
03 Mar 2005, 08:37 PM EST
Msg. 22929 of 22946
Jump to msg. #
From Sterlings Board, Re: CMKX, Looks like we might hear something from the company in a matter of days!
THIS JUST IN..FROM ANDY..YAHOO. (Read 13 times)
tramp
member is online
Gender:
Posts: 2873
THIS JUST IN..FROM ANDY..YAHOO.
« Thread started on: Today at 6:29pm »
--------------------------------------------------------------------------------
Andrew Hill: I have been asked by the attorney to remain quiet pending official clarification from CMKX management over the next day or so. Therefore, I will not be answering the phone on Friday. Please post this up for our shareholders....Tks.
http://cmkxdiamond.proboards32.com/index.cgi?board=general&action=display&num=1109899763
Advertisements
• Trade like a pro with Qcharts
CMKX I am reading a lot of posts on differents boards. I am noticing that some peoples lost total objectivity !!!!.....
Good luck to all,
janet
CMKX from Green Baron:
Thursday afternoon, March 3, 2005
August 2004 Focus Stock Update
CMKM Diamonds, Inc. (PK: CMKX)
SEC Temporarily Suspends Trading of CMKX till March 16th
Early this morning, an employee from Evergreen Marketing, Inc. was told by a representative of Stoecklein Law Group, the recently engaged law firm representing CMKM Diamonds, that a press release would be issued as soon as it is approved to explain more about current events. A call later in the day revealed that Stoecklein Law Group had “no official comment” at this time. The Green Baron Report must hesitate at this particular time to speculate on these matters, but we plan to continue with our in depth coverage of CMKM Diamonds as soon as more information is available.
Below is the SEC’s explanation behind the halt and contact information:
The Securities and Exchange Commission announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (“Exchange Act”), of over-the-counter trading of the securities of CMKM Diamonds, Inc. (Pink Sheets symbol “CMKX”), also known as Casavant Mining Kimberlite International, Inc., of Las Vegas, Nevada. The suspension will commence at 9:30 a.m. EST, March 3, 2005, through 11:59 p.m. EST, on March 16, 2005.
The Commission temporarily suspended trading in the securities of CMKM Diamonds because of questions that have been raised about the adequacy of publicly available information concerning, among other things, CMKM Diamonds’ assets and liabilities, mining and other business activities, share structure and stock issuances, and corporate management. Since the fiscal year ending December 31, 2002, CMKM Diamonds has been delinquent in its periodic filing obligations under Section 13(a) of the Exchange Act. The Commission is concerned that CMKM Diamonds may have unjustifiably relied on a Form S-8 to issue unrestricted securities. The Commission is also concerned that CMKM Diamonds and/or certain of its shareholders may have unjustifiably relied on Rule 144(k) of the Securities Act of 1933 (“Securities Act”) in conducting an unlawful distribution of its securities that failed to comply with the resale restrictions of Rules 144 and 145 of the Securities Act.
The Commission cautions brokers, dealers, shareholders, and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by CMKM Diamonds.
Further, brokers and dealers should be alert to the fact that, pursuant to Rule 15c2-11 under the Exchange Act, at the termination of the trading suspension, no quotation may be entered unless and until they have strictly complied with all of the provisions of the rule. If any broker or dealer has any questions as to whether or not he has complied with the rule, he should not enter any quotation but immediately contact the staff of the Securities and Exchange Commission in Washington, D.C. If any broker or dealer is uncertain as to what is required by Rule 15c2-11, he should refrain from entering quotations relating to the securities of CMKM Diamonds until such time as he has familiarized himself with the rule and is certain that all of its provisions have been met. If any broker or dealer enters any quotation for the stock of CMKM Diamonds that is in violation of the rule, the Commission will consider the need for prompt enforcement action. For questions related to the operation of Rule 15c2-11, please contact the Division of Market Regulation at (202) 942-0069.
If any broker, dealer or other person has any information that may relate to this matter, please contact the CMKM Diamonds Investor Line of the Pacific Regional Office of the Securities and Exchange Commission at (323) 965-4519 or by email at cmkmdiamonds@sec.gov.
Stock to Watch Update
Power2Ship, Inc. (BB: PWRI)
News Alert: Wednesday, March 2 after close of trading:
Legendary Racecar Driver Emerson Fittipaldi Becomes Global Spokesperson for Power2Ship
The Green Baron Report maintains its Stock to Watch status on Power2Ship, but we will monitor events like the one announced late yesterday very close to determine if an upgrade is possible in the future. Please keep PWRI on your radar for further press releases and updates by The Green Baron Report.
BOCA RATON, Fla., Mar 2, 2005 - Power2Ship, Inc., a Web-based Collaborative Marketplace for the freight transportation industry, announced that Emerson Fittipaldi, the world-renowned Formula One racecar driver, has agreed to become the Company's worldwide spokesperson. Fittipaldi has been a successful corporate spokesperson and made numerous personal appearances for many prominent companies such as Michelin, SAP, EMC2, Ericsson, Mercedes-Benz, British Airways, and Hugo Boss. Richard Hersh, Power2Ship's Chairman and CEO commented, "Emerson Fittipaldi's excellent reputation brings a valuable marketing resource to Power2Ship."
In addition, Power2Ship has given Fittipaldi the rights to market the P2S MobileMarket(TM) proprietary freight transportation services to Brazil, one of the world's largest freight transportation markets. Fittipaldi commented, "Power2Ship's MobileMarket(TM) provides a winning solution that maximizes opportunities for all parties involved with transporting freight. I am pleased to become their spokesperson and look forward to introducing their proprietary logistics services to my home country of Brazil."
About Emerson Fittipaldi
Fittipaldi's notoriety came in 1972 when he won his first Formula One title at age 25, making him the youngest driver to ever win a Formula One championship. Two years later, Fittipaldi secured his legacy as one of the greatest drivers in history, winning his second Formula One title. He continued his brilliant performance on the track, winning the CART Championship in 1989 and the Indianapolis 500 in both 1989 and 1993. Fittipaldi ended his 30-year racing career in 1996, after 36 career wins and 23 poles in 339 starts.
About Power2Ship, Inc.
Power2Ship (P2S) is a Web-based Collaborative Marketplace that provides supply chain, tracking and other logistics information that enables freight carriers (trucking companies), shippers (senders and receivers of freight) and their customers to make more-informed, cost-effective transportation/logistics decisions. This information assists P2S Member Shippers to optimize their supply chain and reduce their transportation, warehousing and inventory carrying costs. P2S Member Carriers receive free, unlimited use of an asset management system through the MobileMarket(TM) to track the location, destination and availability of their transportation assets. P2S has formed three new divisions in order to accelerate the market penetration of its patent-pending P2S MobileMarket(TM). An international licensing division will market the P2S MobileMarket(TM) abroad. The second division is focused on Homeland Security and Operation Safe Commerce. The third division is pursuing mergers and acquisitions and joint ventures with strategic transportation and supply chain-related providers.
SOURCE: Power2Ship, Inc.
Power2Ship, Boca Raton
Richard Hersh, 561-998-7557 or 866-727-4995
e-mail: rhersh@power2ship.com
Remove me TheGreenBaron.com Disclaimer